drugset / Trial / NCT03652974

Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

NCT03652974

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).

Timeline

Start
2018-09-06
Primary completion
2021-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 800 mg
Subject Valproate Small molecule 1000 mg
Background Clozapine Other / unclassified 300 mg
Background Clozapine Other / unclassified 600 mg

Indications